> No formal interactions studies with other medicinal products were conducted. Therapeutic monoclonalantibodies do not typically have signif icant drug
-drug interaction potential, as they do not directlyaff ect cytochrome P450 ENZYMES and are not substrates
 of hepatic or renal transporters.Bezlotoxumab
-mediated drug
-drug interactions are unlikely as the target of bezlotoxumab is anexogenous toxin.Concomitant oral standard of care (So
